Skip to main content

Errata - English

PDF CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
ISOTRETINOIN CAPSULES PERFORMANCE TESTS/Dissolution <711>/Test 4 First Supplement to USP36–NF31 6000 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 13 of System suitability: Add section heads before "Calculate the percentage....":
Analysis
Samples: Standard solution and Sample solution
CYCLOBENZAPRINE HYDROCHLORIDE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Second Supplement to USP36–NF31 6585 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 2 of USP Cyclobenzaprine Related Compound A RS: Change
5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-ol.
to:
5-[3-(Dimethylamino)propyl]-5H-dibenzo[a,d]-cyclohepten-5-ol.
TRAMADOL HYDROCHLORIDE ASSAY/Procedure Second Supplement to USP36–NF31 6715 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 2 of System suitability solution: Change
USP Tramadol Hydrochloride Related Compound A RS
to:
USP Tramadol Related Compound A RS
BOSWELLIA SERRATA EXTRACT COMPOSITION/Content of Keto-Derivatives of β-Boswellic Acids/System suitability/Suitability requirements USP36–NF31 1367 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of Tailing factor: Change
11-keto-β-boswellic acid peak
to:
3-acetyl-11-keto-β-boswellic acid peak
CARVEDILOL IMPURITIES/Organic Impurities, Procedure 3: Carvedilol Related Compound F USP36–NF31 2822 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 2 of Sample solution: Change
Use about 1.9 mL of Diluent per mg of the Carvedilol, and sonicate briefly to facilitate dissolution.
to:
Initially add Diluent to fill about 80% of the total volume. Sonicate briefly to facilitate dissolution. Cool, and dilute with… Read More
LEVALBUTEROL INHALATION SOLUTION ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 4080 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 35: Delete
USP Levalbuterol Related Compound H RS
4-[2-(tert-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol.
C14H23NO3 253.34
RISPERIDONE ORALLY DISINTEGRATING TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 5067 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 2 of USP Risperidone Related Compounds Mixture RS: Change
Contains a 98.9/0.5/0.3/0.3 (area %) mixture of the following four compounds:
Risperidone (98.9%)
Risperidone cis-N-oxide (0.5%): cis-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9… Read More
VALERIAN TINCTURE STRENGTH/Content of Valerenic Acids Second Supplement to USP36–NF31 6352 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of Acceptance criteria: Change
90.0%–120.0%
to:
NLT 0.015% of valerenic acids, calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid
PARICALCITOL INJECTION IMPURITIES/Organic Impurities/Chromatographic system/Columns Second Supplement to USP36–NF31 6678 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of Guard: Change
4.6-mm × 7.5-cm
to:
4.6-mm × 7.5-mm
FERRIC AMMONIUM CITRATE Mercury USP36–NF31 2469 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 5 of Standard solutions: Change
2.5, 5.0, 10.0, and 35.0 µg
to:
2.5, 5.0, 10.0, and 35.0 ng
GRANISETRON HYDROCHLORIDE INJECTION Assay USP36–NF31 3772 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 10 of Procedure: Change
100(312.41 / 348.87)(C/L)(rU / rS)
to:
100(312.41 / 348.87)(C/CU)(rU / rS)
AND
Line of 14 of Procedure: Change
L is… Read More
ETHYL OLEATE SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 2006 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Change:
and
to:
or
OXYMETAZOLINE HYDROCHLORIDE OPHTHALMIC SOLUTION Identification USP36–NF31 4652 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
A volume of Ophthalmic Solution, equivalent to about 2.5 mg of oxymetazoline hydrochloride, responds to the Identification test under Oxymetazoline Hydrochloride Nasal Solution.
to:
Place a volume of Ophthalmic Solution, equivalent to about 2.5 mg of… Read More
LINOLEOYL POLYOXYLGLYCERIDES IMPURITIES/Limit of Free Glycerol USP36–NF31 2068 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Mode in Titrimetric system: Change
Direct titration
to:
Residual titration
AND
Line 10 of Analysis: Change
(VSVB)
to:
(VBVS)
AND
Line 11 of Analysis:… Read More
RIVASTIGMINE TARTRATE CHEMICAL INFORMATION USP36–NF31 5073 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
398.41
to:
400.42
POLYSORBATE 80 SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 2163 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
and
to:
or
BACLOFEN ASSAY/Procedure/Chromatographic system First Supplement to USP36–NF31 5951 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Column: Change
250-cm
to:
25.0-cm
SORBITAN MONOSTEARATE IDENTIFICATION/A. USP36–NF31 2214 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
200–215
to:
200–215 on 1-g sample
FILGRASTIM ASSAY/Potency Second Supplement to USP36–NF31 6606 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 7 of Preparation of cells for analysis: Change
Column 1 is filled with 50 L of Medium B.
to:
Column 1 is filled with 50 µL of Medium B.
BUTABARBITAL SODIUM TABLETS Identification, Infrared Absorption <197K> USP36–NF31 2716 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 5 of Test specimen: Change
Proceed as directed for Column Partition Chromatography under Chromatography <621>, packing the chromatographic tube as follows.
to:
Pack a chromatographic tube as follows.
DILUTED ALCOHOL ADDITIONAL REQUIREMENTS USP36–NF31 1874 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Delete USP Reference Standards <11> section
DROSPIRENONE IMPURITIES/Organic Impurities/Procedure 2 USP36–NF31 3349 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 In footnote b of Table 4: Change
5β,17β-Dihydroxy-6β,7β:15β,16β-dimethylene-17α-pregnan-21-carboxylic acid, γ-lactone.
to:
5β,17-Dihydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregnan-21-carboxylic acid, γ-lactone.
CETYL ALCOHOL SPECIFIC TESTS/Fats and Fixed Oils, Hydroxyl Value <401> USP36–NF31 1956 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Mode in Titrimetric system: Change
Direct titration
to:
Residual titration
AND
Line 9 of Analysis: Change
Result = [(VSVB) × F]/W
to:
Result = [(VB Read More
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2/System suitability USP36–NF31 4327 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Capacity factor: Change
NMT 2
to:
NLT 2
HYDROXYETHYL CELLULOSE SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 2038 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
and
to:
or
RIFAMPIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL HYDROCHLORIDE TABLETS Assay for rifampin, isoniazid, and pyrazinamide USP36–NF31 5047 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 12 of Procedure: Change
the Standard preparation and the Assay preparation, respectively.
to:
the Assay preparation and the Standard preparation, respectively.
POLYOXYL 10 OLEYL ETHER SPECIFIC TESTS/Average Polymer Length USP36–NF31 2150 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 9 of Analysis: Change
Result = [(31 A2/A1 − 3)]/4
to:
Result = [(31 × A2/A1) − 3]/4
COMPOUND UNDECYLENIC ACID OINTMENT Assay for zinc undecylenate USP36–NF31 5516 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 15 of Procedure: Change
431.94 is the molecular weight of zinc undecylenate;
to:
Mr is the molecular weight of zinc undecylenate, 431.94;
AND
Line 16 of Procedure: Change
65.39 is the atomic weight of zinc;
to:
Ar… Read More
SORBITAN MONOOLEATE IDENTIFICATION/A. USP36–NF31 2213 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
192–204
to:
192–204 on 1-g sample
QUININE SULFATE TABLETS ASSAY/Procedure First Supplement to USP36–NF31 6046 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 4 of Analysis: Change
dihydroquinone sulfate
to:
dihydroquinine sulfate
STEAROYL POLYOXYLGLYCERIDES IMPURITIES/Limit of Free Glycerol USP36–NF31 2250 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Analysis: Change
(VSVB)
to:
(VBVS)
AND
Line 12 of Analysis: Change
VS = Titrant volume consumed by the Sample… Read More
<232> ELEMENTAL IMPURITIES—LIMITS ANALYTICAL TESTING USP36–NF31 151 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
If, by validated processes and supply-chain control,
to:
If, by process monitoring and supply-chain control,
CARISOPRODOL, ASPIRIN, AND CODEINE PHOSPHATE TABLETS USP Reference standards <11> USP36–NF31 2813 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of USP Codeine N-Oxide RS: Change
C18H21O4
to:
C18H21NO4
CAPRYLOCAPROYL POLYOXYLGLYCERIDES IMPURITIES/Limit of Free Glycerol USP36–NF31 1922 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Mode in Titrimetric system: Change
Direct titration
to:
Residual titration
AND
Line 10 of Analysis: Change
(VTVB)
to:
(VBVS)
AND… Read More
FERUMOXSIL ORAL SUSPENSION Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 3572 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
and
to:
or
FERROSOFERRIC OXIDE IMPURITIES USP36–NF31 2018 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample solution C in Limit of Lead (Pb): Change
Sample solution
to:
Sample stock solution
AND
Line 1 of Sample solution D in Limit of Lead (Pb): Change
Sample solution
to:
Sample stock solution
AND
Line… Read More
POLYVINYL ALCOHOL SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911>, Rotational Rheometer Methods <912>, and Rolling Ball Viscometer Method <913> USP36–NF31 4830 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
and
to:
or
OLEOYL POLYOXYLGLYCERIDES IMPURITIES/Limit of Free Glycerol USP36–NF31 2112 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Mode in Titrimetric system: Change
Direct titration
to:
Residual titration
AND
Line 10 of Analysis: Change
(VSVB)
to:
(VBVS)
AND
Line 11 of Analysis:… Read More
SALICYLIC ACID USP Reference standards <11> USP36–NF31 5098 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of USP Salicylic Acid Related Compound A RS: Change
[CAS-99-96-7].
to:
[99-96-7].
AND
Line 3 of USP Salicylic Acid Related Compound B RS: Change
C8H6O4
to:
C8H6O5
POTASSIUM METAPHOSPHATE SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 2172 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
and
to:
or
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities, Procedure 2 First Supplement to USP36–NF31 5996 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3: Change the section head
Isosorbide mononitrate related compound A stock solution:
to:
Isosorbide mononitrate related compound A standard stock solution:
AND
Line 7: Change the section head
Isosorbide dinitrate stock solution:
to:
Isosorbide… Read More
SORBITAN SESQUIOLEATE IDENTIFICATION/A. USP36–NF31 2215 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
192–204
to:
192–204 on 1-g sample
PANCURONIUM BROMIDE INJECTION IMPURITIES/Organic Impurities Second Supplement to USP36–NF31 6677 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Footnote a of Table 1: Change
Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide.
to:
Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl.
CAFFEINE CITRATE INJECTION Assay USP36–NF31 2732 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of Chromatographic system: Change
150-cm column
to:
15-cm column
BEHENOYL POLYOXYLGLYCERIDES IMPURITIES/Limit of Free Glycerol/Titrimetric system USP36–NF31 1892 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Mode: Change
Direct titration
to:
Residual titration
ESOMEPRAZOLE MAGNESIUM SPECIFIC TESTS/Color of Solution USP36–NF31 3464 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample solution: Change
20 mg/mL of Esomeprazole Magnesium in methanol
to:
20 mg/mL of Esomeprazole Magnesium in methanol, filtered
EGG PHOSPHOLIPIDS ASSAY/Content of Phospholipids USP36–NF31 2000 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Solution A: Change
acetic acid
to:
glacial acetic acid
AND
Line 2 of Solution B: Change
acetic acid
to:
glacial acetic acid
OCTOCRYLENE Identification, Ultraviolet Absorption <197U> USP36–NF31 4557 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 4: Change
Absorptivities, calculated on the as-is basis,
to:
Absorptivity at 303 nm, calculated on the as-is basis,
LAUROYL POLYOXYLGLYCERIDES IMPURITIES/Limit of Free Glycerol USP36–NF31 2064 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Mode in Titrimetric system: Change
Direct titration
to:
Residual titration
AND
Line 10 of Analysis: Change
(VSVB)
to:
(VBVS)
AND
Line 11 of Analysis:… Read More
RIMEXOLONE OPHTHALMIC SUSPENSION Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> USP36–NF31 5053 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1: Change
and
to:
or